LLY Jul 2024 1000.000 call
| Previous Close | 0.5200 |
| Open | 0.5400 |
| Bid | 0.2500 |
| Ask | 0.7500 |
| Strike | 1,000.00 |
| Expire Date | 2024-07-19 |
| Day's Range | 0.5400 - 0.5400 |
| Contract Range | N/A |
| Volume | |
| Open Interest | 221 |
- Reuters
Eli Lilly reaches settlement with spa selling Mounjaro, Zepbound knockoffs
Eli Lilly has entered into a settlement deal with a medi spa that had sold counterfeit versions of its popular diabetes drug Mounjaro and weight loss treatment Zepbound, the drugmaker said on Tuesday. As part of the deal, Totality Medispa will make a monetary payment to Lilly and will no longer use Lilly branding in the promotion of any of its products. The medi spa is expected to take several corrective actions including obtaining and distributing compounded tirzepatide products that are produced in compliance with U.S. federal law.
- Reuters
Wegovy weight loss sustained for four years in trial, Novo Nordisk says
Patients taking Novo Nordisk's popular Wegovy obesity treatment maintained an average of 10% weight loss after four years on the treatment, the company said on Tuesday. Novo presented the new long-term data at the European Congress on Obesity in Venice, Italy, gleaned from a large study for which much of the results had been published last year. "This is the longest study we've conducted so far of semaglutide for weight loss," Martin Holst Lange, Novo's head of development, said in an interview, referring to the active ingredient in Wegovy and the company's diabetes drug Ozempic.
ZacksPharma Stock Roundup: PFE DMD Study Patient Death, FDA Panel Meet for LLY's Donanemab
Pfizer (PFE) reports the death of a participant in a mid-stage study of its Duchenne drug. An FDA panel meeting to discuss Eli Lilly's (LLY) donanemab is set to take place on Jun 10.
